Maria Giuseppina Marini
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Maria Giuseppina Marini has a total of 72 co-authors. Here are the top co-authors by number of shared publications:
- Paolo Moi
Istituto di Clinica e Biologia dell'Età Evolutiva, Università di Cagliari. Ospedale Regionale per le Microcitemie, 09121 Cagliari, Italy
11 shared publications Antonio Cao
Istituto di Neurogenetica e Neurofarmacologia, Consiglio Nazionale delle Ricerche, Cagliari
4 shared publicationsIsadora Asunis
Istituto di Neurogenetica e Neurofarmacologia, Consiglio Nazionale delle Ricerche, Cagliari
3 shared publicationsLoredana Porcu
Dipartimento di Scienze Biomediche e Biotecnologie, Università di Cagliari, Italy
3 shared publicationsA. Cao
2 shared publicationsA. Meloni
2 shared publications
Latest Publications
- 20 November 2020
- Published by Wiley in British Journal of Haematology
- Vol. 192 (2) , 395-404
Induction of therapeutic levels of HbF in genome‐edited primary β039‐thalassaemia haematopoietic stem and progenitor cells
Summary: Hereditary persistence of fetal haemoglobin (HPFH) is the major modifier of the clinical severity of β‐thalassaemia. The homozygous mutation c.‐196 C>T in the Aγ‐globin (HBG1) promoter, which causes Sardinian δβ0‐thalassaemia, is able to completely rescue the β‐major thalassaemia phenotype caused by the β039‐thalassaemia mutation, ensuring high levels of fetal haemoglobin synthesis during adulthood. Here, we describe a CRISPR/Cas9 genome‐editing approach, combined with the non‐homologous end joining (NHEJ) pathway repair, aimed at reproducing the effects of this naturally occurring HPFH mutation in both HBG promoters. After selecting the most efficient guide RNA in K562 cells, we edited the HBG promoters in human umbilical cord blood‐derived erythroid progenitor 2 cells (HUDEP‐2) and in haematopoietic stem and progenitor cells (HSPCs) from β0‐thalassaemia patients to assess the therapeutic potential of HbF induction. Our results indicate that small deletions targeting the −196‐promoter region restore high levels of fetal haemoglobin (HbF) synthesis in all cell types tested. In pools of HSPCs derived from homozygous β039‐thalassaemia patients, a 20% editing determined a parallel 20% increase of HbF compared to unedited pools. These results suggest that editing the region of HBG promoters around the −196 position has the potential to induce therapeutic levels of HbF in patients with most types of β‐thalassaemia irrespective of the β‐globin gene (HBB) mutations.
- 20 November 2020
- Published by Wiley in British Journal of Haematology
- Vol. 192 (2) , 395-404
Induction of therapeutic levels of HbF in genome‐edited primary β039‐thalassaemia haematopoietic stem and progenitor cells
Summary: Hereditary persistence of fetal haemoglobin (HPFH) is the major modifier of the clinical severity of β‐thalassaemia. The homozygous mutation c.‐196 C>T in the Aγ‐globin (HBG1) promoter, which causes Sardinian δβ0‐thalassaemia, is able to completely rescue the β‐major thalassaemia phenotype caused by the β039‐thalassaemia mutation, ensuring high levels of fetal haemoglobin synthesis during adulthood. Here, we describe a CRISPR/Cas9 genome‐editing approach, combined with the non‐homologous end joining (NHEJ) pathway repair, aimed at reproducing the effects of this naturally occurring HPFH mutation in both HBG promoters. After selecting the most efficient guide RNA in K562 cells, we edited the HBG promoters in human umbilical cord blood‐derived erythroid progenitor 2 cells (HUDEP‐2) and in haematopoietic stem and progenitor cells (HSPCs) from β0‐thalassaemia patients to assess the therapeutic potential of HbF induction. Our results indicate that small deletions targeting the −196‐promoter region restore high levels of fetal haemoglobin (HbF) synthesis in all cell types tested. In pools of HSPCs derived from homozygous β039‐thalassaemia patients, a 20% editing determined a parallel 20% increase of HbF compared to unedited pools. These results suggest that editing the region of HBG promoters around the −196 position has the potential to induce therapeutic levels of HbF in patients with most types of β‐thalassaemia irrespective of the β‐globin gene (HBB) mutations.
- Open Access
- 28 October 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0141083
A Novel High-Content Immunofluorescence Assay as a Tool to Identify at the Single Cell Level γ-Globin Inducing Compounds
The identification of drugs capable of reactivating γ-globin to ameliorate β-thalassemia and Sickle Cell anemia is still a challenge, as available γ-globin inducers still have limited clinical indications. High-throughput screenings (HTS) aimed to identify new potentially therapeutic drugs require suitable first-step-screening methods combining the possibility to detect variation in the γ/β globin ratio with the robustness of a cell line. We took advantage of a K562 cell line variant expressing β-globin (β-K562) to set up a new multiplexed high-content immunofluorescence assay for the quantification of γ- and β-globin content at single-cell level. The assay was validated by using the known globin inducers hemin, hydroxyurea and butyric acid and further tested in a pilot screening that confirmed HDACs as targets for γ-globin induction (as proved by siRNA-mediated HDAC3 knockdown and by treatment with HDACs inhibitors entinostat and dacinostat) and identified Heme-oxygenases as novel candidate targets for γ-globin induction. Indeed, Heme-oxygenase2 siRNA knockdown as well as its inhibition by Tin protoporphyrin-IX (TinPPIX) greatly increased γ-globin expression. This result is particularly interesting as several metalloporphyrins have already been developed for clinical uses and could be tested (alone or in combination with other drugs) to improve pharmacological γ-globin reactivation for the treatment of β-hemoglobinopathies.
- 28 October 2015
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 10 (10) , e0141083
Open AccessA Novel High-Content Immunofluorescence Assay as a Tool to Identify at the Single Cell Level γ-Globin Inducing Compounds
The identification of drugs capable of reactivating γ-globin to ameliorate β-thalassemia and Sickle Cell anemia is still a challenge, as available γ-globin inducers still have limited clinical indications. High-throughput screenings (HTS) aimed to identify new potentially therapeutic drugs require suitable first-step-screening methods combining the possibility to detect variation in the γ/β globin ratio with the robustness of a cell line. We took advantage of a K562 cell line variant expressing β-globin (β-K562) to set up a new multiplexed high-content immunofluorescence assay for the quantification of γ- and β-globin content at single-cell level. The assay was validated by using the known globin inducers hemin, hydroxyurea and butyric acid and further tested in a pilot screening that confirmed HDACs as targets for γ-globin induction (as proved by siRNA-mediated HDAC3 knockdown and by treatment with HDACs inhibitors entinostat and dacinostat) and identified Heme-oxygenases as novel candidate targets for γ-globin induction. Indeed, Heme-oxygenase2 siRNA knockdown as well as its inhibition by Tin protoporphyrin-IX (TinPPIX) greatly increased γ-globin expression. This result is particularly interesting as several metalloporphyrins have already been developed for clinical uses and could be tested (alone or in combination with other drugs) to improve pharmacological γ-globin reactivation for the treatment of β-hemoglobinopathies.
- Open Access
- 17 May 2010
- Published by Wiley in British Journal of Haematology
- Vol. 149 (5) , 748-758
Regulation of the humanHBAgenes by KLF4 in erythroid cell lines
Summary: KLF1/EKLF and related Krueppel‐like factors (KLFs) are variably implicated in the regulation of theHBB‐like globin genes. Prompted by the observation that four KLF sites are distributed in the human α‐globin gene (HBA) promoter, we investigated if KLFs could also act to modulate the expression of theHBAgenes. Among the KLFs tested, only KLF4/GKLF bound specifically to three out of four α‐globin KLF sites. The occupancy of the same sites by KLF4in vivowas confirmed by chromatin immunoprecipitation assays with KLF4‐specific antibodies. In luciferase reporter assays in MEL cells, high levels of the wild typeHBApromoter, but not mutated promoters bearing point mutations that disrupted KLF4‐DNA binding, were transactivated by over‐expression of KLF4. In K562 cells, induced KLF4 expression with a Tet‐off regulated cassette stimulated the expression of the endogenousHBAgenes. In a complementary assay in the same cell line, knocking down KLF4 with lentiviral delivered sh‐RNAs caused a parallel decrease in the transcription of theHBAgenes. All experiments combined support a regulatory role of KLF4 in the control ofHBAgene expression.
- 17 May 2010
- Published by Wiley in British Journal of Haematology
- Vol. 149 (5) , 748-758
Open AccessRegulation of the humanHBAgenes by KLF4 in erythroid cell lines
Summary: KLF1/EKLF and related Krueppel‐like factors (KLFs) are variably implicated in the regulation of theHBB‐like globin genes. Prompted by the observation that four KLF sites are distributed in the human α‐globin gene (HBA) promoter, we investigated if KLFs could also act to modulate the expression of theHBAgenes. Among the KLFs tested, only KLF4/GKLF bound specifically to three out of four α‐globin KLF sites. The occupancy of the same sites by KLF4in vivowas confirmed by chromatin immunoprecipitation assays with KLF4‐specific antibodies. In luciferase reporter assays in MEL cells, high levels of the wild typeHBApromoter, but not mutated promoters bearing point mutations that disrupted KLF4‐DNA binding, were transactivated by over‐expression of KLF4. In K562 cells, induced KLF4 expression with a Tet‐off regulated cassette stimulated the expression of the endogenousHBAgenes. In a complementary assay in the same cell line, knocking down KLF4 with lentiviral delivered sh‐RNAs caused a parallel decrease in the transcription of theHBAgenes. All experiments combined support a regulatory role of KLF4 in the control ofHBAgene expression.
- 9 February 2010
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 118 (03) , 177-179
A Novel Missense Mutation (C84R) in a Patient with Type II Vitamin D-dependent Rickets
A 7-year-old boy with severe rickets that by clinical analysis was diagnosed as affected by type II vitamin D-dependent rickets, was evaluated for mutations in the vitamin D receptor gene (VDR). The molecular analysis showed a homozygous state for a novel missense mutation (C84R) in a highly conserved nucleotide in the second Zn finger of the DNA binding domain.
- 9 February 2010
- Published by Georg Thieme Verlag KG in Experimental and Clinical Endocrinology & Diabetes
- Vol. 118 (03) , 177-179
A Novel Missense Mutation (C84R) in a Patient with Type II Vitamin D-dependent Rickets
A 7-year-old boy with severe rickets that by clinical analysis was diagnosed as affected by type II vitamin D-dependent rickets, was evaluated for mutations in the vitamin D receptor gene (VDR). The molecular analysis showed a homozygous state for a novel missense mutation (C84R) in a highly conserved nucleotide in the second Zn finger of the DNA binding domain.
- 2 February 2010
- Published by Hindawi Limited in Human Mutation
- Vol. 31 (4) , 456-465
ΔN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region
The transcription of the ΔN133p53 isoform of the TP53 gene is controlled by an internal promoter region (IPR) containing eight polymorphisms in 11 common haplotypes, following a resequencing of 47 Caucasians. We assayed the functional effects of the commonest six haplotypes on the promoter activity with a luciferase reporter system, in HeLa and 293T cells. These studies showed that different IPR haplotypes are associated with differences in the promoter activity resulting in marked variation in the baseline expression of ΔN133p53. In vivo quantitative‐polymerase chain reaction (PCR) on human tissues confirmed that the baseline levels of ΔN133p53 showed haplotype specific differences that paralleled those seen in vitro. When cell lines were treated with camptothecin, the fold‐increase in ΔN133p53 levels was dose‐dependent but haplotype‐independent (i.e., similar for all the haplotypes). Finally, we used an electrophoretic mobility shift assay to analyze the rs1794287 polymorphism and found changes in the pattern of protein binding. This partially confirmed our in silico analysis showing that the polymorphism rs1794287 can affect the function of the internal promoter by changing its affinity for several transcription factors. Thus, we showed that the expression of ΔN133p53 is under genetic control, and suggested the presence of interindividual differences underlying this mechanism. Hum Mutat 31:1–10, 2010.
- 2 February 2010
- Published by Hindawi Limited in Human Mutation
- Vol. 31 (4) , 456-465
ΔN133p53 expression levels in relation to haplotypes of the TP53 internal promoter region
The transcription of the ΔN133p53 isoform of the TP53 gene is controlled by an internal promoter region (IPR) containing eight polymorphisms in 11 common haplotypes, following a resequencing of 47 Caucasians. We assayed the functional effects of the commonest six haplotypes on the promoter activity with a luciferase reporter system, in HeLa and 293T cells. These studies showed that different IPR haplotypes are associated with differences in the promoter activity resulting in marked variation in the baseline expression of ΔN133p53. In vivo quantitative‐polymerase chain reaction (PCR) on human tissues confirmed that the baseline levels of ΔN133p53 showed haplotype specific differences that paralleled those seen in vitro. When cell lines were treated with camptothecin, the fold‐increase in ΔN133p53 levels was dose‐dependent but haplotype‐independent (i.e., similar for all the haplotypes). Finally, we used an electrophoretic mobility shift assay to analyze the rs1794287 polymorphism and found changes in the pattern of protein binding. This partially confirmed our in silico analysis showing that the polymorphism rs1794287 can affect the function of the internal promoter by changing its affinity for several transcription factors. Thus, we showed that the expression of ΔN133p53 is under genetic control, and suggested the presence of interindividual differences underlying this mechanism. Hum Mutat 31:1–10, 2010.
- Open Access
- 2 September 2004
- Published by Wiley in British Journal of Haematology
- Vol. 127 (1) , 114-117
The distal β‐globin CACCC box is required for maximal stimulation of the β‐globin gene by EKLF
Summary: The transcription factor erythroid Kruppel‐like factor (EKLF) specifically activates the β‐globin gene by interacting with the proximal β‐globin CACCC box, a known hot spot for thalassaemia mutations. This study investigated whether EKLF could also bind to, and activate from, the distal CACCC, which is a rare site of thalassaemia mutations. Using band shift and transient expression analysis with wild type, single and double CACCC mutants, we established that the distal CACCC box is weakly bound by EKLF, but, when mutated, significantly impairs EKLF‐dependent β‐globin stimulation. Thus, EKLF requires both CACCC boxes to maximally stimulate the β‐globin gene.
- 2 September 2004
- Published by Wiley in British Journal of Haematology
- Vol. 127 (1) , 114-117
Open AccessThe distal β‐globin CACCC box is required for maximal stimulation of the β‐globin gene by EKLF
Summary: The transcription factor erythroid Kruppel‐like factor (EKLF) specifically activates the β‐globin gene by interacting with the proximal β‐globin CACCC box, a known hot spot for thalassaemia mutations. This study investigated whether EKLF could also bind to, and activate from, the distal CACCC, which is a rare site of thalassaemia mutations. Using band shift and transient expression analysis with wild type, single and double CACCC mutants, we established that the distal CACCC box is weakly bound by EKLF, but, when mutated, significantly impairs EKLF‐dependent β‐globin stimulation. Thus, EKLF requires both CACCC boxes to maximally stimulate the β‐globin gene.
- Open Access
- 16 August 2004
- Published by Wiley in British Journal of Haematology
- Vol. 126 (6) , 881-884
A novel silent β‐thalassemia mutation in the distal CACCC box affects the binding and responsiveness to EKLF
The silent β‐thalassemia mutation, β+‐101C→T, is the only mutation currently described in the distal β‐globin CACCC box. We present a novel mutation, a C→G transversion, in the same position. Expression analysis in heterozygous subjects demonstrated that the mutation determines a 20% reduction in the output of the β‐globin gene. DNA–protein interaction and transactivation analysis correlated the decrease in the β‐globin synthesis with the reduced binding and transactivation of EKLF to the mutant promoter. These data predict that the β‐101C→G mutation will display a silent thalassemia phenotype similar to that of the β‐101C→T mutation.
- 16 August 2004
- Published by Wiley in British Journal of Haematology
- Vol. 126 (6) , 881-884
Open AccessA novel silent β‐thalassemia mutation in the distal CACCC box affects the binding and responsiveness to EKLF
The silent β‐thalassemia mutation, β+‐101C→T, is the only mutation currently described in the distal β‐globin CACCC box. We present a novel mutation, a C→G transversion, in the same position. Expression analysis in heterozygous subjects demonstrated that the mutation determines a 20% reduction in the output of the β‐globin gene. DNA–protein interaction and transactivation analysis correlated the decrease in the β‐globin synthesis with the reduced binding and transactivation of EKLF to the mutant promoter. These data predict that the β‐101C→G mutation will display a silent thalassemia phenotype similar to that of the β‐101C→T mutation.
- 1 September 2002
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 29 (2) , 145-158
Cloning MafF by Recognition Site Screening with the NFE2 Tandem Repeat of HS2: Analysis of Its Role in Globin and GCSl Genes Regulation
- 1 September 2002
- Published by Elsevier in Blood Cells, Molecules, and Diseases
- Vol. 29 (2) , 145-158
Cloning MafF by Recognition Site Screening with the NFE2 Tandem Repeat of HS2: Analysis of Its Role in Globin and GCSl Genes Regulation
- 1 June 2002
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 25 (6) , 557-560
A novel splicing defect (IVS6+1G>T) in a patient with pseudovitamin D deficiency rickets
A 15-month-old boy with severe rickets, that by clinical analysis was diagnosed as affected by hereditary pseudovitamin D deficiency rickets (PDDR), was evaluated for mutations in the 25OHD3 1α-hydroxylase gene. Molecular analysis showed a double heterozygous state for a novel splicing mutation in the invariant dinucleotide of the donor site of IVS6 and a 7 nucleotide insertion in the exon 8, which is common in different ethnical backgrounds.
- 1 June 2002
- Published by Springer Nature in Journal of Endocrinological Investigation
- Vol. 25 (6) , 557-560
A novel splicing defect (IVS6+1G>T) in a patient with pseudovitamin D deficiency rickets
A 15-month-old boy with severe rickets, that by clinical analysis was diagnosed as affected by hereditary pseudovitamin D deficiency rickets (PDDR), was evaluated for mutations in the 25OHD3 1α-hydroxylase gene. Molecular analysis showed a double heterozygous state for a novel splicing mutation in the invariant dinucleotide of the donor site of IVS6 and a 7 nucleotide insertion in the exon 8, which is common in different ethnical backgrounds.
- Open Access
- 1 June 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (26) , 16490-16497
hMAF, a Small Human Transcription Factor That Heterodimerizes Specifically with Nrf1 and Nrf2
- 1 June 1997
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 272 (26) , 16490-16497
Open AccesshMAF, a Small Human Transcription Factor That Heterodimerizes Specifically with Nrf1 and Nrf2